Profile | GDS2987 / GI_15431319-S |
Title | Comparison of Rho kinase inhibitor and atorvastatin effects on primary cell lines |
Organism | Homo sapiens |
Sample | Title | Value | Rank |
---|---|---|---|
GSM214810 | HMVEC_vehicle_rep1 | ||
GSM215244 | HMVEC_vehicle_rep2 | 21.1 | 47 |
GSM215253 | HMVEC_vehicle_rep3 | 1.7 | 6 |
GSM215254 | HMVEC_atorvastatin_rep1 | 3.3 | 9 |
GSM215282 | HMVEC_atorvastatin_rep3 | ||
GSM215344 | HMVEC_atorvastatin_rep2 | ||
GSM215283 | HMVEC_atorvastatin_mevalonate_rep1 | ||
GSM215284 | HMVEC_atorvastatin_mevalonate_rep2 | ||
GSM215293 | HMVEC_atorvastatin_mevalonate_rep3 | ||
GSM215294 | HMVEC_SLx2119_rep1 | ||
GSM215295 | HMVEC_SLx2119_rep2 | ||
GSM215296 | HMVEC_SLx2119_rep3 | ||
GSM215297 | PASMC_vehicle_rep1 | 7.3 | 12 |
GSM215298 | PASMC_vehicle_rep2 | 20.7 | 31 |
GSM215310 | PASMC_vehicle_rep3 | 19.9 | 31 |
GSM215311 | PASMC_atorvastatin_rep1 | 7.3 | 13 |
GSM215312 | PASMC_atorvastatin_rep2 | ||
GSM215313 | PASMC_atorvastatin_rep3 | ||
GSM215324 | PASMC_atorvastatin_mevalonate_rep1 | 11.8 | 20 |
GSM215325 | PASMC_atorvastatin_mevalonate_rep2 | 11.9 | 24 |
GSM215326 | PASMC_atorvastatin_mevalonate_rep3 | ||
GSM215327 | PASMC_SLx2119_rep1 | 4.4 | 8 |
GSM215328 | PASMC_SLx2119_rep2 | 6.9 | 13 |
GSM215329 | PASMC_SLx2119_rep3 | ||
GSM215330 | Fibroblasts_vehicle_rep1 | 129.5 | 77 |
GSM215331 | Fibroblasts_vehicle_rep2 | 116.7 | 76 |
GSM215332 | Fibroblasts_vehicle_rep3 | 123.5 | 77 |
GSM215333 | Fibroblasts_atorvastatin_rep1 | 123.3 | 77 |
GSM215334 | Fibroblasts_atorvastatin_rep2 | 127.9 | 77 |
GSM215335 | Fibroblasts_atorvastatin_rep3 | 119 | 76 |
GSM215336 | Fibroblasts_atorvastatin_mevalonate_rep1 | 80 | 73 |
GSM215337 | Fibroblasts_atorvastatin_mevalonate_rep2 | 105.9 | 76 |
GSM215338 | Fibroblasts_atorvastatin_mevalonate_rep3 | 88.1 | 74 |
GSM215339 | Fibroblasts_SLx2119_rep1 | 191.8 | 81 |
GSM215340 | Fibroblasts_SLx2119_rep2 | 226.3 | 83 |
GSM215341 | Fibroblasts_SLx2119_rep3 | 162.1 | 79 |